miR-382 inhibits migration and invasion by targeting ROR1 through regulating EMT in ovarian cancer

被引:70
作者
Tan, Hong [1 ,2 ]
He, Qingnan [3 ]
Gong, Guanhui [2 ]
Wang, Yixuan [1 ,2 ]
Li, Juanni [1 ,2 ]
Wang, Junpu [1 ,2 ]
Zhu, Ding [1 ,2 ]
Wu, Xiaoying [1 ,2 ]
机构
[1] Cent S Univ, Dept Pathol, Sch Basic Med Sci, Changsha 410013, Hunan, Peoples R China
[2] Cent S Univ, Dept Pathol, Xiangya Hosp, Changsha 410008, Hunan, Peoples R China
[3] Cent S Univ, Childrens Med Ctr, Xiangya Hosp 2, Changsha 410011, Hunan, Peoples R China
基金
中国国家自然科学基金;
关键词
miR-382; ovarian cancer; receptor tyrosine kinase orphan receptor 1; epithelial-mesenchymal transition; migration; invasion; EPITHELIAL-MESENCHYMAL TRANSITION; MICRORNAS; DIAGNOSIS; PROGNOSIS; METASTASIS; CARCINOMA; MIRNAS;
D O I
10.3892/ijo.2015.3241
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Increasing evidence suggests that microRNAs (miRNAs) play a critical role in tumorigenesis. Decreased expression of miR-382 has been observed in various types of cancers. However, the biological function of miRNA-382 in ovarian cancer is still largely unknown. Here, we found miR-382 was downregulated in human ovarian cancer tissues and cell lines. miR-382 inhibited ovarian cancer cell proliferation, migration, invasion and the epithelial-mesenchymal transition (EMT). Furthermore, we identified receptor tyrosine kinase orphan receptor 1 (ROR1) as a target of miR-382, and miR-382 rescued the promotion effect of ROR1 on migration, invasion and EMT process in SKOV3 and COV434 cells. Collectively, these findings revealed that miR-382 inhibits migration and invision by targeting ROR1 through regulating EMT in ovarian cancer, and might serve as a tumor suppressor in ovarian cancer.
引用
收藏
页码:181 / 190
页数:10
相关论文
共 30 条
  • [1] Böcker W, 2002, VERH DEUT G, V86, P116
  • [2] Identification of miR-187 and miR-182 as Biomarkers of Early Diagnosis and Prognosis in Patients with Prostate Cancer Treated with Radical Prostatectomy
    Casanova-Salas, Irene
    Rubio-Briones, Jose
    Calatrava, Ana
    Mancarella, Caterina
    Masia, Esther
    Casanova, Juan
    Fernandez-Serra, Antonio
    Rubio, Luis
    Ramirez-Backhaus, Miguel
    Arminan, Ana
    Dominguez-Escrig, Jose
    Martinez, Francisco
    Garcia-Casado, Zaida
    Scotlandi, Katia
    Vicent, Maria J.
    Antonio Lopez-Guerrero, Jose
    [J]. JOURNAL OF UROLOGY, 2014, 192 (01) : 252 - 259
  • [3] Targeting ROR1 Inhibits Epithelial-Mesenchymal Transition and Metastasis
    Cui, Bing
    Zhang, Suping
    Chen, Liguang
    Yu, Jianqiang
    Widhopf, George F., II
    Fecteau, Jessie-F.
    Rassenti, Laura Z.
    Kipps, Thomas J.
    [J]. CANCER RESEARCH, 2013, 73 (12) : 3649 - 3660
  • [4] MicroRNAs in ovarian carcinomas
    Dahiya, Neetu
    Morin, Patrice J.
    [J]. ENDOCRINE-RELATED CANCER, 2010, 17 (01) : F77 - F89
  • [5] Roles for MicroRNAs in Conferring Robustness to Biological Processes
    Ebert, Margaret S.
    Sharp, Phillip A.
    [J]. CELL, 2012, 149 (03) : 515 - 524
  • [6] Goff BA, 2000, CANCER, V89, P2068, DOI 10.1002/1097-0142(20001115)89:10<2068::AID-CNCR6>3.0.CO
  • [7] 2-Z
  • [8] The Role of miRNA in Haematological Malignancy
    Gounaris-Shannon, Stephanie
    Chevassut, Timothy
    [J]. BONE MARROW RESEARCH, 2013,
  • [9] Timeline - The discovery of receptor tyrosine kinases: targets for cancer therapy
    Gschwind, A
    Fischer, OM
    Ullrich, A
    [J]. NATURE REVIEWS CANCER, 2004, 4 (05) : 361 - 370
  • [10] Treatment of ovarian cancer beyond chemotherapy: Are we hitting the target?
    Ingles Garces, Alvaro Henrique
    Fontes Dias, Mariane Sousa
    Paulino, Eduardo
    Moreira Ferreira, Carlos Gil
    de Melo, Andreia Cristina
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 75 (02) : 221 - 234